JP7027325B2 - 炭酸無水酵素ｉｘを標的とする薬剤および方法 - Google Patents

炭酸無水酵素ｉｘを標的とする薬剤および方法 Download PDF

Info

Publication number
JP7027325B2
JP7027325B2 JP2018549202A JP2018549202A JP7027325B2 JP 7027325 B2 JP7027325 B2 JP 7027325B2 JP 2018549202 A JP2018549202 A JP 2018549202A JP 2018549202 A JP2018549202 A JP 2018549202A JP 7027325 B2 JP7027325 B2 JP 7027325B2
Authority
JP
Japan
Prior art keywords
conjugate
pharmaceutically acceptable
formula
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018549202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512511A (ja
JP2019512511A5 (enExample
Inventor
フィリップ・エス・ロウ
ペンチェン・ル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2019512511A publication Critical patent/JP2019512511A/ja
Publication of JP2019512511A5 publication Critical patent/JP2019512511A5/ja
Application granted granted Critical
Publication of JP7027325B2 publication Critical patent/JP7027325B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
JP2018549202A 2016-03-16 2017-03-16 炭酸無水酵素ｉｘを標的とする薬剤および方法 Expired - Fee Related JP7027325B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662309264P 2016-03-16 2016-03-16
US201662309268P 2016-03-16 2016-03-16
US62/309,268 2016-03-16
US62/309,264 2016-03-16
PCT/US2017/022785 WO2017161170A1 (en) 2016-03-16 2017-03-16 Carbonic anhydrase ix targeting agents and methods

Publications (3)

Publication Number Publication Date
JP2019512511A JP2019512511A (ja) 2019-05-16
JP2019512511A5 JP2019512511A5 (enExample) 2020-04-23
JP7027325B2 true JP7027325B2 (ja) 2022-03-01

Family

ID=59852046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549202A Expired - Fee Related JP7027325B2 (ja) 2016-03-16 2017-03-16 炭酸無水酵素ｉｘを標的とする薬剤および方法

Country Status (6)

Country Link
US (2) US11925696B2 (enExample)
EP (1) EP3429575A4 (enExample)
JP (1) JP7027325B2 (enExample)
AU (1) AU2017234676A1 (enExample)
CA (1) CA3017214A1 (enExample)
WO (1) WO2017161170A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161170A1 (en) 2016-03-16 2017-09-21 Purdue Research Foundation Carbonic anhydrase ix targeting agents and methods
EP3429637A4 (en) * 2016-03-16 2020-03-11 Endocyte, Inc. CONJUGATES OF CARBONIC ANHYDRASE IX INHIBITORS AND USES THEREOF
US20210322582A1 (en) * 2018-08-30 2021-10-21 Nihon Medi-Physics Co., Ltd. Radioactive imidazothiadiazole derivative compound
AU2024266164A1 (en) * 2023-05-02 2025-10-30 Rayzebio, Inc. Radiopharmaceutical compositions targeting carbonic anhydrase ix and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2260875T3 (da) * 2002-05-06 2014-06-30 Endocyte Inc Folatreceptor-targetede billeddannelsesmidler
AU2004211584B2 (en) * 2003-01-31 2009-11-12 Promega Corporation Covalent tethering of functional groups to proteins
US20060211074A1 (en) * 2005-01-12 2006-09-21 Boyce James P Kinase-directed, activity-based probes
CN103893778A (zh) 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
US20090043099A1 (en) 2006-03-17 2009-02-12 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
PT2187965T (pt) * 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
CN101596433B (zh) 2009-07-15 2011-07-06 中国科学院工程热物理研究所 U形返料器的冷却式隔板
FR2951449B1 (fr) 2009-10-15 2011-11-25 Commissariat Energie Atomique Procede de fonctionnalisation de molecules biologiques
WO2011090710A2 (en) * 2009-12-28 2011-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composite probes and use thereof in super resolution methods
WO2011098610A1 (en) * 2010-02-12 2011-08-18 Universita Degli Studi Di Firenze Carbonic anhydrase inhibitors
JP5544239B2 (ja) * 2010-07-29 2014-07-09 富士フイルム株式会社 重合性組成物
EP2707102B1 (en) * 2011-05-09 2019-11-13 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
HUE068833T2 (hu) 2011-08-17 2025-01-28 Merck & Cie Kmg Albumint megkötõ egységek folát konjugátjai
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US10183970B2 (en) 2014-01-28 2019-01-22 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
US9771380B2 (en) 2014-06-09 2017-09-26 University Of Oregon Gold nanoparticles and methods of making and using gold nanoparticles
WO2017161170A1 (en) 2016-03-16 2017-09-21 Purdue Research Foundation Carbonic anhydrase ix targeting agents and methods
CA3019835A1 (en) * 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2014年，Vol.57，p.9673-9686

Also Published As

Publication number Publication date
US20240316224A1 (en) 2024-09-26
US20190083663A1 (en) 2019-03-21
WO2017161170A1 (en) 2017-09-21
US11925696B2 (en) 2024-03-12
CA3017214A1 (en) 2017-09-21
JP2019512511A (ja) 2019-05-16
EP3429575A1 (en) 2019-01-23
EP3429575A4 (en) 2019-10-23
AU2017234676A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
US11872291B2 (en) Fibroblast activation protein (FAP)-targeted imaging and therapy
US11883498B2 (en) Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof
US20240316224A1 (en) Carbonic anhydrase ix targeting agents and methods
JP2023099047A (ja) 炭酸脱水酵素陽性がんを標的とするｆｂｓａ系治療および放射性造影複合体
US10857234B2 (en) Carbonic anhydrase IX inhibitor conjugates and uses thereof
US12508319B2 (en) Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof
HK40016572A (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
HK40016572B (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
HK40031566A (en) Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
HK40016594B (en) Fibroblast activation protein (fap)-targeted imaging and therapy
HK40016594A (en) Fibroblast activation protein (fap)-targeted imaging and therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220216

R150 Certificate of patent or registration of utility model

Ref document number: 7027325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees